Niagen Bioscience Profit Margin

The latest profit margin for NAGE is 53.69% as of June 2026. That compares with 27.68% in the prior-year period — up 93.9% year over year. That is above the Healthcare sector average of 10.58%. Investors often review this figure alongside Niagen Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, NAGE's profit margin moved from 27.68% to 53.69% — a 93.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Niagen Bioscience's valuation or profitability profile.

Against Healthcare companies, NAGE currently prints 53.69% for profit margin, while the sector average sits near 10.58%. That is roughly 407.4% above the sector mean. Large gaps often invite a closer look at Niagen Bioscience's growth, margins, and balance sheet.

Profit Margin shows how effectively Niagen Bioscience converts resources into returns. At 53.69%, NAGE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 27.68% in the prior-year period — up 93.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NAGE's profit margin (53.69%), review year-over-year change from 27.68%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.